Kantarjian HM - Search Results

1

Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.

Kantarjian HM, Stein AS, Bargou RC, Grande Garcia C, Larson RA, Stelljes M, Gökbuget N, Zugmaier G, Benjamin JE, Zhang A, Jia C, Topp MS. Kantarjian HM, et al. Cancer. 2016 Jul 15;122(14):2178-85. doi: 10.1002/cncr.30031. Epub 2016 May 3. Cancer. 2016. PMID: 27143254 Free article.

2

Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia.

Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Talpaz M, et al. Cancer. 1992 Jan 15;69(2):410-2. doi: 10.1002/1097-0142(19920115)69:2<410::aid-cncr2820690222>3.0.co;2-v. Cancer. 1992. PMID: 1370212

3

CI-973, a new platinum derivative with potential antileukemic activity.

O'Brien S, Kantarjian H, Freireich E, Johnston D, Nguyen K, Beran M. O'Brien S, et al. Cancer Res. 1992 Aug 1;52(15):4130-4. Cancer Res. 1992. PMID: 1638526

4

Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients.

Talpaz M, Chernajovsky Y, Troutman-Worden K, Wetzler M, Kantarjian H, Gutterman JU, Kurzrock R. Talpaz M, et al. Cancer Res. 1992 Mar 1;52(5):1087-90. Cancer Res. 1992. PMID: 1737366

5

Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.

O'Brien S, Kantarjian H, Estey E, Koller C, Beran M, McCredie K, Keating M. O'Brien S, et al. Cancer. 1991 Aug 15;68(4):691-4. doi: 10.1002/1097-0142(19910815)68:4<691::aid-cncr2820680404>3.0.co;2-z. Cancer. 1991. PMID: 1855168

6

Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia.

Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Schilling PJ, et al. Cancer. 1991 Oct 1;68(7):1536-7. doi: 10.1002/1097-0142(19911001)68:7<1536::aid-cncr2820680713>3.0.co;2-b. Cancer. 1991. PMID: 1893353

7

A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.

Talpaz M, Kurzrock R, Kantarjian H, Rothberg J, Saks S, Evans L, Gutterman JU. Talpaz M, et al. Cancer. 1991 Nov 15;68(10):2125-30. doi: 10.1002/1097-0142(19911115)68:10<2125::aid-cncr2820681006>3.0.co;2-q. Cancer. 1991. PMID: 1913450 Clinical Trial.

8

Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission.

O'Brien S, Witt R, Talpaz M, Kantarjian H. O'Brien S, et al. Cancer. 1991 Apr 1;67(7):1946-9. doi: 10.1002/1097-0142(19910401)67:7<1946::aid-cncr2820670720>3.0.co;2-#. Cancer. 1991. PMID: 2004308

9

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.

Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W. Grunewald R, et al. Cancer Res. 1990 Nov 1;50(21):6823-6. Cancer Res. 1990. PMID: 2208147

10

High-dose chemotherapy and unpurged autologous bone marrow transplantation for acute leukemia in second or subsequent remission.

Spinolo JA, Dicke KA, Horwitz LJ, Jagannath S, McCredie K, Estey E, Kantarjian H, Zander AR, Keating M, Spitzer G. Spinolo JA, et al. Cancer. 1990 Aug 15;66(4):619-26. doi: 10.1002/1097-0142(19900815)66:4<619::aid-cncr2820660403>3.0.co;2-z. Cancer. 1990. PMID: 2386890

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,088 results

Search Page

Filters